@FierceMedDev: ICYMI yesterday: Study: Fecal incontinence implants reduce weekly incontinence episodes in women. Article | Follow @FierceMedDev
@VarunSaxena2: Novel epitope for binding of HIV antibodies has major drug delivery implications. FierceDrugDelivery story | Follow @VarunSaxena2
@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. Report | Follow @MichaelGFierce
@EmilyWFierce: Physicians find little difference between old and new orthopedic implants, suggest "facts box" for knee & hip devices. MedPage Today article | Follow @EmilyWFierce
> Nanowear, an early-stage developer of wearable, textile-based diagnostic monitoring technology, announced a $1.5 million seed investment round led by The Social+Capital Partnership and MAS Holdings (Pvt.) Limited. Release
> Harpoon Medical, a device company specializing in minimally invasive, beating heart mitral valve repair technology, raised $3.2 million in a Series A funding round. Release
> Thoratec started enrollment for its U.S. clinical trial of its centrifugal-flow chronic left ventricular assist system, HeartMate III. Release
Biotech News
@FierceBiotech: FDA panel spurns $ACT's cardio combo, jeopardizing its potential. Story | Follow @FierceBiotech
@JohnCFierce: Xenon pitches Genentech, Teva "extreme genetics" ties as it rolls out a $52M. News | Follow @JohnCFierce
@DamianFierce: $AGN and Ackman have resorted to WWE-level taunts and provocations and it hasn't stopped being entertaining. Article via Reuters | Follow @DamianFierce
@EmilyMFierce: Compound inhibits both MERS, SARS. More | Follow @EmilyMFierce
> R&D pioneer tackles the next hurdle in gene therapy: Paying for $1M-plus drugs. More
> Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice. Article
> Genmab re-ups with Seattle Genetics on a $211M armed antibody cancer drug pact. Story
Pharma News
@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Perrigo recalls 367,000 tubes of nicotine lozenges. Story | Follow @FiercePharma
@EricPFierce: Cipla is spending $17M to buy two plants from one of its contractors. Report | Follow @EricPFierce
@CarlyHFierce: ICYMI, Our latest special report - The top 10 best-selling MS drugs of 2013 - is here. Report | Follow @CarlyHFierce
> With $1M gene therapies coming, research pioneer and CVS plot new payment route. More
> Wake up, Ackman tells Allergan's board. He has a 50%-60% chance of replacing you. Story
Drug Delivery News
> Microneedle patch delivers painkiller to second layer of skin in 5 minutes. Report
> Low T products under FDA scrutiny over safety concerns. Item
> Novaliq dissolvable drops improve eye quality in clinical trials. Story
> HIV-fighting intravaginal ring research nets $20M from NIH. More
> Novel epitope for binding of HIV antibodies has major drug delivery implications. Article
Diagnostics News
> Veracyte grabs Allegro Diagnostics for $21M and jumps into lung cancer test space. News
> U.K. test may help Roche's cancer drug Avastin target ideal patients. More
> GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. Report
> ASCO: Provista's autoantibody/biomarker combo boosts breast cancer screening accuracy. Article
> Myriad's multigene predictive cancer test shows utility in new trial. Story
Pharma Marketing News
> Attention market-access experts: NICE won't take pharma's word on cost-effectiveness anymore. Item
> Think a $150K cancer drug is pricey? Try a $1M-plus gene therapy. Editor's corner
> Teva goes analog for asthma with hands-on waiting-room game. Article
> Auxilium's Low-T woes put sales reps in line for layoffs. Story
> Free speech, PhRMA? Not in this off-label marketing case, feds say. More